In a nutshell This study compared the occurrence of infections and identified their risk factors in patients with rheumatoid arthritis (RA) that were treated with tofacitinib (Xeljanz) against those given a tumor necrosis factor inhibitor (TNFi). The data showed that serious and non-serious infections were higher in patients that received...
Read More
In a nutshell This study evaluated the 7-year follow-up remission rate and maintenance in patients with rheumatoid arthritis (RA) under real-life conditions and identified factors related to long-term remission. The authors concluded that at 7 years nearly twice as many patients were in remission than at 1 year of follow-up and those patients had mainly...
Read More
In a nutshell This study evaluated the effectiveness and safety of rituximab (Rituxan) biosimilar HLX01 combined with methotrexate (MTX; Trexall) in patients with moderate to severe rheumatoid arthritis (RA) following inadequate responses to MTX. The study showed that HLX01 added to MTX resulted in improvements compared to placebo in these...
Read More
In a nutshell This study assessed the effectiveness and safety of daily administered prednisolone (Prelone) at a dose of 5 mg, as an add-on to the standard of care (SOC) in older patients with rheumatoid arthritis (RA). The authors concluded that low-dose prednisolone added to SOC had long-term benefits in these patients with a favorable balance of...
Read More
In a nutshell This review evaluated the safety and effectiveness of vitamin E supplementation in patients with rheumatoid arthritis (RA). The authors concluded that regular supplementation with vitamin E can help to improve the overall quality of life (QoL) in patients by reducing joint discomfort, swelling due to excessive fluid buildup in tissues...
Read More
In a nutshell This analysis compared the effectiveness of different acupuncture therapies combined with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). The data indicated that RA disease activity was most improved by combining electro-acupuncture and DMARDs while fire-needle or moxibustion plus DMARDs...
Read More
In a nutshell This study identified predictors of disease flare in patients with early, active rheumatoid arthritis (RA) that had stopped methotrexate (MTX; Otrexup) and/or abatacept (Orencia) treatment after clinical remission was achieved at 12 months. The data showed that patient function (HAQ-DI) and bone erosion based on magnetic resonance...
Read More
In a nutshell This review evaluated the effectiveness of denosumab (Prolia) on bone mineral density (BMD) and joint destruction in patients with rheumatoid arthritis (RA). The authors concluded that denosumab treatment was linked to increased BMD and reduced joint destruction in patients with RA. Some background RA is a chronic inflammatory...
Read More
In a nutshell This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to...
Read More
In a nutshell This study evaluated immune responses after two doses of SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases including rheumatoid arthritis (RA) compared to healthy controls (HCs). The data showed that patients with inflammatory joint diseases had similar responses to mRNA vaccines after 2...
Read More
In a nutshell This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a...
Read More
In a nutshell This study assessed the responses of patients with rheumatoid arthritis (RA) to tofacitinib (Xeljanz), tofacitinib with methotrexate (MTX; Otrexup), and adalimumab (Humira) with MTX. The data showed that some patients did not require combined therapy to achieve higher responses, however, overall, greater responses were achieved with...
Read More
